Profile:
Professor Dajani has broad expertise in clinical pharmacology, toxicology, drug development, regulatory affairs, patents and Contract Research Organizations (CROs). He has over 30 years experience in pharmaceutical research and development. He was most instrumental in the discovery and development of Cyotec, a worldwide anti-ulcer drug. He is the founder and president of IDDC Corporation, a CRO which provides consulting services for pharmaceutical companies, law firms and governmental agencies. He also holds Adjunct Professor of Medicine appointment at Loyola University Chicago and previously held Adjunct Professor of Pharmacology appointment at Chicago Medical School. He provides investigations, research, record analysis, consultation, merit statement and testimony.

Years as Expert: 20 Years

Alternate email address: Esam.Dajani@gmail.com

Education/Licenses:
PhD (Pharmacology & Toxicology), MS (Pharmacology & Medicinal Chemistry), BS (Pharmacy), Licensed Pharmacist.

Primary Area of Expertise:
Pharmacology